The variables selected by LASSO regression included age, smoking history, prior pulmonary disease, adverse events during neoadjuvant chemoimmunotherapy, post-treatment impaired pulmonary function, lymph node metastasis, and preoperative interleukin-6 (IL-6) elevation. This evidence concerns the gene IL6 and lung disorder.